CN108289876A - 针对癌症的美乐芬剂量方案 - Google Patents

针对癌症的美乐芬剂量方案 Download PDF

Info

Publication number
CN108289876A
CN108289876A CN201680070133.3A CN201680070133A CN108289876A CN 108289876 A CN108289876 A CN 108289876A CN 201680070133 A CN201680070133 A CN 201680070133A CN 108289876 A CN108289876 A CN 108289876A
Authority
CN
China
Prior art keywords
dose
metropene
salt
patients
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680070133.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·林德伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncopeptides AB
Original Assignee
Oncopeptides AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55177548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108289876(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncopeptides AB filed Critical Oncopeptides AB
Publication of CN108289876A publication Critical patent/CN108289876A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680070133.3A 2015-12-01 2016-12-01 针对癌症的美乐芬剂量方案 Pending CN108289876A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1521217.8 2015-12-01
GBGB1521217.8A GB201521217D0 (en) 2015-12-01 2015-12-01 Dosage regimens
PCT/EP2016/079511 WO2017093443A1 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer

Publications (1)

Publication Number Publication Date
CN108289876A true CN108289876A (zh) 2018-07-17

Family

ID=55177548

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680070133.3A Pending CN108289876A (zh) 2015-12-01 2016-12-01 针对癌症的美乐芬剂量方案

Country Status (27)

Country Link
US (3) US20180369141A1 (enExample)
EP (3) EP3383385B2 (enExample)
JP (2) JP6878431B2 (enExample)
KR (2) KR20210092327A (enExample)
CN (1) CN108289876A (enExample)
AU (2) AU2016363591B2 (enExample)
BR (1) BR112018010012A8 (enExample)
CA (1) CA3003102C (enExample)
CY (1) CY1123469T1 (enExample)
DK (1) DK3383385T4 (enExample)
ES (1) ES2828033T5 (enExample)
FI (1) FI3383385T4 (enExample)
GB (1) GB201521217D0 (enExample)
HR (1) HRP20201632T4 (enExample)
HU (1) HUE051525T2 (enExample)
IL (2) IL259101A (enExample)
LT (1) LT3383385T (enExample)
MX (2) MX384724B (enExample)
PL (1) PL3383385T5 (enExample)
PT (1) PT3383385T (enExample)
RS (1) RS60986B2 (enExample)
RU (2) RU2020134307A (enExample)
SG (1) SG11201803551YA (enExample)
SI (1) SI3383385T2 (enExample)
SM (1) SMT202000567T1 (enExample)
WO (1) WO2017093443A1 (enExample)
ZA (2) ZA201802816B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114026121A (zh) * 2019-01-28 2022-02-08 赛诺菲 治疗多发性骨髓瘤的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019362389B2 (en) * 2018-10-18 2024-12-12 Oncopeptides Innovation Ab Compounds containing deuterium
CN114025753A (zh) * 2019-04-03 2022-02-08 肿瘤多肽有限公司 用美氟芬治疗al淀粉样变性
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) * 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
SE544998C2 (en) * 2021-01-13 2023-02-21 Bkmdcl Ab Peptide conjugates of melphalan for the treatment of cancer
EP4366721A1 (en) * 2021-07-08 2024-05-15 Oncopeptides Innovation AB Melflufen for use in the treatment of multiple myeloma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104994847A (zh) * 2012-10-26 2015-10-21 肿瘤多肽股份公司 美法仑氟灭酰胺的冻干制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
RS56462B1 (sr) * 2011-04-28 2018-01-31 Oncopeptides Ab Liofilizovani preparat citotoksičnih dipeptida
EP2909690B1 (en) 2012-10-22 2017-07-19 Parker Hannifin Manufacturing Sweden AB Joystick for utility vehicles
EA032775B1 (ru) * 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104994847A (zh) * 2012-10-26 2015-10-21 肿瘤多肽股份公司 美法仑氟灭酰胺的冻干制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLAUDIA PABA-PRADA等: "Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)", 《BLOOD》 *
V. MAGAROTTO等: "ENCOURAGING PRELIMINARY DATA IN ONGOING OPEN-LABEL PHASE1/2 STUDY OF SAFETY AND EFFICACY OF MELFLUFEN AND *DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA", 《HAEMATOLOGICA JOURNAL OF THE EUROPEAN HEMATOLOGY ASSOCIATION》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114026121A (zh) * 2019-01-28 2022-02-08 赛诺菲 治疗多发性骨髓瘤的方法

Also Published As

Publication number Publication date
JP2019501881A (ja) 2019-01-24
IL301019B2 (en) 2025-12-01
ZA201802816B (en) 2021-07-28
EP3383385A1 (en) 2018-10-10
CA3003102A1 (en) 2017-06-08
AU2016363591A1 (en) 2018-06-28
MX384724B (es) 2025-03-14
MX2018006706A (es) 2018-08-01
HRP20201632T1 (hr) 2021-01-08
ES2828033T5 (es) 2024-04-04
EP3903777A1 (en) 2021-11-03
ES2828033T3 (es) 2021-05-25
US20250144023A1 (en) 2025-05-08
EP3383385B1 (en) 2020-07-29
FI3383385T4 (fi) 2023-11-01
SMT202000567T1 (it) 2020-11-10
HUE051525T2 (hu) 2021-03-01
EP3750534A1 (en) 2020-12-16
ZA202102438B (en) 2025-08-27
SG11201803551YA (en) 2018-05-30
CA3003102C (en) 2022-09-13
DK3383385T3 (da) 2020-10-12
PL3383385T3 (pl) 2021-05-04
GB201521217D0 (en) 2016-01-13
US20220047507A1 (en) 2022-02-17
RS60986B2 (sr) 2023-12-29
RU2018123718A (ru) 2020-01-09
RS60986B1 (sr) 2020-11-30
PT3383385T (pt) 2020-10-26
RU2020134307A (ru) 2020-11-27
PL3383385T5 (pl) 2023-12-18
IL259101A (en) 2018-06-28
MX2021008738A (es) 2021-08-24
US20180369141A1 (en) 2018-12-27
HRP20201632T4 (hr) 2023-11-10
KR20180087254A (ko) 2018-08-01
LT3383385T (lt) 2020-12-28
KR20210092327A (ko) 2021-07-23
BR112018010012A8 (pt) 2019-02-26
IL301019A (en) 2023-05-01
CY1123469T1 (el) 2022-03-24
RU2018123718A3 (enExample) 2020-04-02
AU2016363591B2 (en) 2020-12-10
NZ742548A (en) 2023-10-27
DK3383385T4 (da) 2023-11-06
WO2017093443A1 (en) 2017-06-08
EP3383385B2 (en) 2023-09-06
JP6878431B2 (ja) 2021-05-26
SI3383385T1 (sl) 2020-11-30
SI3383385T2 (sl) 2024-01-31
BR112018010012A2 (pt) 2018-11-21
JP2021088560A (ja) 2021-06-10
RU2734930C2 (ru) 2020-10-26
IL301019B1 (en) 2025-08-01
KR102279629B1 (ko) 2021-07-20
AU2021200436A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
US20250144023A1 (en) Melflufen dosage regimens for cancer
CN111787945B (zh) 作为癌症免疫治疗的检查点阻断剂的工程化纳米囊泡
US20230212201A1 (en) Stat3 degraders and uses thereof
JP2021091690A (ja) 急性骨髄性白血病（ａｍｌ）のための新規併用治療
ES2913073T3 (es) Direccionamiento del sistema inmunitario innato para inducir tolerancia a largo plazo y resolver la acumulación de macrófagos en aterosclerosis
JP2011515405A (ja) ジチオカルバメート金属キレートならびにその作製および使用方法
CN112135639B (zh) 细胞组装介导的癌症免疫治疗检查点抑制剂的递送
JP2014525449A (ja) デシタビン誘導体製剤
JP2022515670A (ja) ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの組成物及び使用方法
TWI776451B (zh) Bcl-2/bcl-xl抑制劑之組合及相關用途
NZ742548B2 (en) Melflufen dosage regimens for cancer
CA3206959A1 (en) Methods for treating and ameliorating cancer
US20220233652A1 (en) Pharmaceutical Compositions Comprising Integration-Promoting Peptides
HK1260696A1 (en) Melflufen dosage regimens for cancer
HK1260696B (en) Melflufen dosage regimens for cancer
US20230210793A1 (en) Method for rapid infusion of carmustine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180717

RJ01 Rejection of invention patent application after publication